Dexcom Continuous Glucose Monitoring (CGM) features demonstrate proven outcomes in A1C reduction, time in range (TIR), and improved device adherence.1,2,5,6 Dexcom ranks #1 in patient satisfaction,† adherence, and retention.7,9,‡
Company Background
Dexcom, Inc. empowers people to take control of health through innovative CGM systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world.
Product Overview
Dexcom G7 is the simple CGM for effortless diabetes management. The low-profile, all-in-one wearable sensor has a lightning fast 30-minute warmup — 2x faster than any other CGM.§ Users will receive real-timeglucose readings automatically on their compatible smart device|| or Dexcom receiver, no fingersticks¶ required. Dexcom G7 also offers a suite of customizable alerts that can warn of high or low glucose levels with a predictive low alert that can recognize potentially dangerous hypoglycemic incidents before they occur.
Dexcom CGM has demonstrated a >1% A1C reduction after 12 weeks.1,2,5 Dexcom G7 can help patients reach their glycemic goals and improve their quality of life.1-5,10 Dexcom is a preferred CGM of national payors on the pharmacy benefit.11,# As the most covered CGM brand,7,** Dexcom requires only one prescription that can be easily sent directly to pharmacy for a quick, simple start and low out-of-pocket costs.7,‡‡
Dexcom G7 is an integrated CGM (iCGM) indicated for the widest age range and across diabetes types (type 1, type 2, and gestational diabetes) and treatment types (basal insulin, noninsulin, glucagon-like peptide-1). No other CGM system is more affordable than Dexcom G7 for Medicare patients.‡‡ For more information on affordability programs, please visit dexcom.com/savings.
Features & Options
Dexcom G7 is the most connected CGM system7:
• Two times faster warmup than any other CGM.§
• Dexcom is the only CGM brand currently powering AID systems that allows up to 10 people in your circle to follow you.
• The first and only CGM with no fingersticks from day one.¶
• Only CGM with app features that help protect from severe hypoglycemia and diabetic ketoacidosis.
• Dexcom has powered over 1.7 million patient-years on AID systems.7
• Dexcom G7 is the most connected CGM system,7 connecting to Tandem, Lily Tempo, Insulet Omnipod, and Beta Bionics devices.
Testimonials
Dexcom is the most affordable CGM brand7, §§:
• Dexcom CGM is the #1 recommended CGM by patients.12
• 96% of patients said the Dexcom G7 CGM System was easy to use.13
• Dexcom ranks #1 in patient satisfaction,† adherence, and retention.7-9,‡
• Dexcom is a preferred CGM of national payors on the pharmacy benefit.11,#
• 98% of people have coverage for Dexcom G7.7,‡‡,||||
• 3 out of 4 Medicare Advantage patients pay $0 at the pharmacy.7,†† Savings programs are available for patients without CGM coverage.
Ordering Information
To order, please contact your pharmacy wholesale partner. Dexcom G7 is available to order from all major wholesalers.
*Compared to self-monitoring of blood glucose.
†Based on a comparison in net promoter scores across major CGM brands.
‡IQVIA paid sensor claims at 12 months.
§ Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour
or longer.
||Smart devices sold separately. For a list of compatible devices, visit dexcom.com/compatibility.
¶Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
#Individual coverage may vary depending on commercial pharmacy coverage benefits.
**Individual coverage may vary depending on insurance plan.
††Individual pricing may vary depending on insurance coverage.
‡‡ Under Medicare’s durable medical equipment (DME) fee schedule, reimbursement and coinsurance for
CGM using Current Procedural Terminology (CPT) codes A4239 and E2103, are the same, regardless of CGM brand.
§§ Most affordable refers to claims at pharmacy. Individual pricing may vary depending on insurance coverage.
||||Includes both pharmacy and medical benefit.
1 Beck RW, et al. JAMA. 2017;317(4):371-378. 2 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374. 3 Martens T, et al. JAMA. 2021;325(22):2262-2272. 4 Laffel LM, et al. JAMA. 2020;323(23):2388-2396. 5 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-147. 6 Nemlekar P, et al. Diabetes Ther. 2024;15(3):639- 648. 7 Dexcom, data on file, 2024. 8 DQ&A Q1 2023 Patient Perspectives. 9 Seagrove Patient Perspectives, 2021. 10 Gilbert TR, Diabetes Technol Ther. 2021;23(S1):S35-S9. 11 Managed Markets Insights & Technology, LLC. MMIT Analytics April-June 2024. 12 dQ&A US Q1 2023 US Diabetes Connections Patient Panel Report. 13 Dexcom G7 User Guide, 2025.
